17R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
FILSPARI Commercial GrowthRapid FILSPARI growth across IgA nephropathy and FSGS demonstrates strong product adoption and expanding commercial reach. Continued demand growth can improve operating leverage, support reinvestment in the pipeline, and strengthen Travere’s position in rare kidney disease over the next several quarters.
Product Differentiation And IPClinical differentiation, durable extension data, and advancing method-of-use protection can reinforce physician and payer confidence in FILSPARI. These attributes may support continued prescribing, help defend the commercial franchise, and make the product’s revenue base more durable as competition develops.
Pipeline ExpansionA progressing Phase III program and the addition of civorebrutinib broaden Travere beyond its current commercial product. Pipeline diversification creates potential future growth avenues, increases the value of the rare-disease platform, and reduces reliance on a single marketed therapy over time.
Bears Say
Very High LeverageThe sharply increased debt burden and thin equity base leave limited protection against operating setbacks. Although cash generation has improved, substantial leverage can constrain investment flexibility, increase refinancing exposure, and direct future cash toward financing obligations rather than growth.
Profitability Not Yet DurableRevenue growth and high gross margins have not yet translated into consistent bottom-line or operating profitability. Persistent losses and only marginal EBITDA leave less internal funding for pipeline investment and make sustainable earnings dependent on further scale, expense discipline, and commercial execution.
Competitive And Access PressureNew entrants can increase competition for prescribers, patients, and payer coverage, potentially raising the commercial effort needed to sustain FILSPARI growth. Ongoing education requirements may lengthen adoption and increase selling complexity, especially as Travere expands across distinct kidney disease indications.
Travere Therapeutics News
17R FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is CHF4.06B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Feb 25, 2027 which is in 125 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Aug 04, 2026. The company reported -CHF0.304 earnings per share for the quarter, missing the consensus estimate of -CHF0.111 by -CHF0.193.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Travere Therapeutics have?
Currently, no data Available
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -CHF0.304 in its last earnings report, missing expectations of -CHF0.111. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in CH:17R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF62.59 (― Upside)
CHF62.59 (― Upside)
Blogger Sentiment
Neutral
CH:17R Sentiment 56%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.13%
12-Months-Change
Fundamentals
Return on Equity
-55.79%
Trailing 12-Months
Asset Growth
43.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
17R Company Deck
17R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and a positive growth trajectory: record FILSPARI demand and revenue, an encouraging FSGS launch that outpaced early IgA nephropathy uptake, meaningful pipeline additions (pegtibatinase and civorebrutinib), an IP allowance for IgAN methods, and a reinforced balance sheet following convertible refinancing. Offsetting items include elevated operating expenses, a $40M inducement expense, a $112.5M upfront payment for civorebrutinib (post-quarter), expected higher gross-to-net discounts in H2, and limited disclosure of granular commercial metrics and FSGS-specific IP outcomes. On balance, the strengths and growth drivers substantially outweigh the near-term costs and disclosure gaps reported in the quarter.View all CH:17R earnings summaries17R Stock 12 Month Forecast
Average Price Target
―Ionis Pharmaceuticals
―
Omeros
―
Aurinia Pharmaceuticals
―
Immunovant
―
Vera Therapeutics
―